Lortan Tablet 50 mg

국가: 싱가포르

언어: 영어

출처: HSA (Health Sciences Authority)

유효 성분:

Losartan Potassium

제공처:

ORGANON SINGAPORE PTE. LTD.

ATC 코드:

C09CA01

복용량:

50 mg

약제 형태:

TABLET, COATED

구성:

Losartan Potassium 50 mg

관리 경로:

ORAL

처방전 유형:

Prescription Only

Manufactured by:

Organon Pharma (UK) Limited

승인 상태:

ACTIVE

승인 날짜:

2007-03-23

제품 특성 요약

PRODUCT CIRCULAR
SG-OG0954(G)-T-102021
LORTAN Tablet
(losartan potassium)
USE IN PREGNANCY
Drugs that act directly on the renin-angiotensin system can cause
injury and even death in the developing
fetus. When pregnancy is detected, discontinue LORTAN as soon as
possible.
I. THERAPEUTIC CLASS
LORTAN (losartan potassium), the first of a new class of
antihypertensives, is an angiotensin II receptor (type
AT
1
) antagonist. LORTAN also provides a reduction in the risk of stroke
in hypertensive patients with left
ventricular hypertrophy and renal protection for type 2 diabetic
patients with proteinuria.
II. INDICATIONS
Hypertension
LORTAN is indicated for the treatment of hypertension.
Hypertensive Patients with Left Ventricular Hypertrophy
LORTAN is indicated for the reduction in the risk of stroke in
hypertensive patients with left ventricular
hypertrophy (see RACE).
Renal Protection in Type 2 Diabetic Patients with Proteinuria
LORTAN is indicated to delay the progression of renal disease as
measured by a reduction in the incidence
of doubling of serum creatinine and end stage renal disease (need for
dialysis or renal transplantation), and
to reduce proteinuria.
III. DOSAGE AND ADMINISTRATION
LORTAN may be administered with or without food.
LORTAN may be administered with other antihypertensive agents.
Hypertension
The usual starting and maintenance dose is 50 mg once daily for most
patients. The maximal antihypertensive
effect is attained 3-6 weeks after initiation of therapy. Some
patients may receive an additional benefit by
increasing the dose to 100 mg once daily.
For patients with intravascular volume-depletion (e.g., those treated
with high-dose diuretics), a starting dose
of 25 mg once daily should be considered (see PRECAUTIONS).
No initial dosage adjustment is necessary for elderly patients up to
75 years of age, or for patients with mild
renal impairment. For patients above 75 years of age, patients with
moderate to severe renal impairment and
patients on dialysis, a lower starting dose of 25 mg is recomm